Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population Authors: Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G Kennedy, Julie MacDougall Published: 2026 ABSTRACT AbstractBackground:Adalimumab is an antitumor necrosis factor agent approved by the U.S. Food and Drug Administration in 2002 for the treatment of various rheumatologic diseases. Recent approval of adalimumab biosimilars presents an important area of study to determine real-world efficacy and cost savings of biosimilars.Objectives:The primary objective was to evaluate the impact of nonmedical, insurance-mandated adalimumab switches on disease activity. The secondary objective was to assess the financial impact of these biosimilar switches.Methods:A retrospective cohort study was conducted of patients with rheumatic diseases who experienced payer-mandated switches to biosimilars. The primary outcome was change in disease activity, defined by provider assessment documented in the electronic health record before switching and at follow-up. Analyses were completed using chi-square or Fisher exact tests for categorical variables and t tests, analysis of variance (ANOVA), or nonparametric equivalents for continuous variables, with P < .05 required for statistical significance.Results:A total of 152 patients were included; among patients controlled at baseline, 84/119 (70.6%) remained unchanged and 35/119 (29.4%) worsened. Among those partially controlled at baseline, 6/17 (35.3%) improved, 7/17 (41.2%) remained unchanged, and 4/17 (23.5%) worsened. Among patients with active disease at baseline, 9/12 (75.0%) improved and 3/12 (25.0%) remained unchanged. Median out-of-pocket copay change was $0.Conclusion:Insurance-mandated switches did not appear to meaningfully impact disease control for most patients. In addition, median out-of-pocket costs did not change after switching. These findings should reassure pharmacists when helping patients with insurance-mandated adalimumab biosimilar switches.Keywords: adalimumab, rheumatology, biosimilar, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis Background Approximately 4 million adalimumab and adalimumab biosimilar prescriptions are dispensed annually in the United States. 1 Adalimumab is a humanized IgG1 anti-tumor necrosis factor (TNF) monoclonal antibody that binds directly to TNF alpha, preventing it from binding to its corresponding receptors and halting the resulting inflammatory cascade.2,3 Humira (adalimumab) was initially approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis (RA). As of 2025, adalimumab is FDA-approved for psoriatic arthritis (PsA), juvenile Idiopathic arthritis (JIA), ankylosing spondylitis (AS), plaque psoriasis, Crohn disease (CD), ulcerative colitis (UC), hidradenitis suppurativa (HS), and noninfectious uveitis. There has been an increase in the use of FDA approved adalimumab biosimilars in recent years: Amjevita (adalimumab-atto) approved in 2016, Cyltezo (adalimumab-adbm) in 2017, Hyrimoz (adalimumab-adaz) in 2018, Idacio (adalimumab-aacf) and Hadlima (adalimumab-bwwd) in 2019, Hulio (adalimumab-fkjp) in 2020, Yuflyma (adalimumab-aaty) in 2023, and Simlandi (adalimumab-ryvk) in 2024. 2 A biosimilar, as defined by the FDA, is a biological product that is made to be highly similar to the reference product and is required to demonstrate the same efficacy and safety profile. 4 However, a biosimilar will not be identical to the reference product as these are made from living organisms. Manufacturers can achieve interchangeable status by submitting additional data to the FDA demonstrating that patients can alternate from reference product to biosimilar without clinically meaningful differences. 5 This interchangeable status allows pharmacies to substitute the reference product with a biosimilar without prescriber approval. The American College of Rheumatology recommends a treat-to-target approach for patients, meaning treatment goals are individualized based on patient characteristics and disease state. 6 Generally, once a patient is considered clinically stable, medication therapy will not be changed. However, financial barriers can arise if the treatment of choice is no longer preferred by the patient’s insurance payer or if out-of-pocket (OOP) costs become unaffordable. The purpose of this study was to evaluate disease activity following nonmedical, insurance-mandated switching from adalimumab reference product to adalimumab biosimilar among a cohort of patients within a rheumatology clinic. Methods This was a retrospective, pre-post study of adults seen at a rheumatology clinic within a health network, with patients serving as their own controls. University of Vermont Health is a 6-hospital system serving patients in Vermont and northern New York. The rheumatology clinic includes embedded clinical pharmacists who manage patients through a collaborative practice agreement. Eligible patients were adults aged 18 years and older with a rheumatologic diagnosis limited to rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis on reference adalimumab for at least 3 months and switched to an adalimumab biosimilar between January 1, 2022, and August 15, 2025. All switches were nonmedical and insurance-mandated. Patients were excluded if they did not have a qualifying diagnosis, never started the biosimilar, or if documentation was incomplete. Demographic data, inflammatory markers, disease activity, and cost data were collected at baseline and post-switch. Demographic data included age, race, ethnicity, gender identity, and diagnosis. Inflammatory markers included pre-post baseline C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Disease activity data included Routine Assessment of Patient Index Data 3 (RAPID3) scores, flares, discontinuation of biosimilar, number of hospitalizations due to flare, addition of disease-modifying antirheumatic drug (DMARD) therapy, dose and/or frequency changes to biologic treatment, and provider assessments of disease activity. Cost data included OOP costs and use of copay or medication assistance programs (eg, manufacturer discount program). Electronic health record data were collected using manual chart review and managed using REDCap electronic data capture tools. 7 This study was approved by the University of Vermont Committees on Human Research (STUDY00003834). The primary objective of this study was to determine whether switching from the adalimumab reference product to biosimilar changed disease activity as measured by documented provider assessments of disease activity. The secondary objective was to compare OOP copay costs between the reference product and biosimilar after the switch. Patients were assessed on the use of copay assistance and the exact copay amount in dollars for both the reference product and the biosimilar. Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). Continuous variables were summarized using means and standard deviations or medians and interquartile range. Comparison of outcomes used analysis of variance (ANOVA) for parametric analyses. Nonparametric alternatives such as Wilcoxon rank sum, Wilcoxon signed rank, and Kruskal-Wallis tests were used if distributional assumptions were not met, or if data were highly skewed. Routine Assessment of Patient Index Data 3 comparisons used paired t tests and were further confirmed with nonparametric signed rank tests. P < .05 was required for statistical significance. Results A total of 311 patients were screened for eligibility and 152 met inclusion criteria. Of the 159 that were excluded, 29 never started the biosimilar, 64 lacked a qualifying diagnosis, and the remaining 66 were excluded for incomplete documentation. Among the 152 patients included, the most commonly prescribed biosimilar was adalimumab-ryvk at 46.1% (n = 70), followed by adalimumab-bwwd at 16.5% (n = 25), adalimumab-adbm at 14.5% (n = 22), and adalimumab-adaz at 13.8% (n = 21). The remaining biosimilars, adalimumab-atto, adalimumab-aaty, adalimumab-aacf, and adalimumab-aqvh, each accounted for less than 5% of switches. The 152 patients had a median age of 54 years (interquartile range [IQR] 43, 61). A majority were female (59.5%), white (94.1%), and commercially insured (83.7%). The most common diagnosis was rheumatoid arthritis (44.7%), and 80.3% of patients were controlled at baseline per provider assessment (Table 1). Table 1.Baseline Demographics.CharacteristicN(%)Total152(100)Age (years, IQR)54.0(43.0, 61.0)Female sex91(59.5)Race White143(94.1) African American or black3(2.0) Other or patient declines to respond6(3.9)Insurance Commercial127(83.7) Medicaid2(1.3) Medicare23(15.0)Diagnosis Rheumatoid arthritis68(44.7) Psoriatic arthritis55(36.2) Ankylosing spondylitis29(19.1)Disease control at baseline Controlled122(80.3) Partially controlled17(11.2) Active disease12(7.9) Baseline Demographics. Among patients controlled at baseline, 70.6% (84/119) remained unchanged and 29.4% (35/119) worsened after the biosimilar switch; no patients in this group improved, as controlled disease represented the lowest disease activity category. Those who were partially controlled at baseline, 35.3% (6/17) improved, 41.2% (7/17) remained unchanged, and 23.5% (4/17) worsened. Among patients with active disease at baseline, 75.0% (9/12) improved and 25.0% (3/12) remained unchanged (Supplemental Figure 1). The direction of disease-state change differed significantly by baseline disease group (P < .0001; Table 2), and the proportion of patients with any disease-state change also differed significantly by baseline disease-control group (chi-square/Fisher exact P = .0010) (Supplemental Table 1). These findings suggest that post-switch disease-state outcomes varied substantially by baseline status, with worsening concentrated among patients controlled at baseline and improvement observed primarily in the smaller partially controlled and active disease subgroups (Table 2, Supplemental Table 2). Table 2.Clinical Outcomes Post-Switch Stratified by Baseline Status.Baseline groupN(%)Controlled post-switch119 a (100) Worsened35(29.4) No change84(70.6) Improved0(0.0)Partially controlled post-switch17(100) Worsened4(23.5) No change7(41.2) Improved6(35.3)Active disease post-switch12(100) Worsened0(0.0) No change3(25) Improved9(75)Overall comparison< .0001 b aA total of 119/122 from baseline demographics were not captured due to telemedicine/pharmacy encounters/lost to follow-up.bPearson chi-square test for the 3 × 3 table. Direction of provider-assessed disease-state change differed significantly by baseline disease-control group (P < .0001). Clinical Outcomes Post-Switch Stratified by Baseline Status. A total of 119/122 from baseline demographics were not captured due to telemedicine/pharmacy encounters/lost to follow-up. Pearson chi-square test for the 3 × 3 table. Direction of provider-assessed disease-state change differed significantly by baseline disease-control group (P < .0001). Clinical status at baseline in relation to flares did not reach statistical significance post-switch (P = .07). Of the patients controlled at baseline,73.3% (88/119) did not flare or experience worsening disease activity post-switch. A slight majority of patients within the partially controlled group also remained stable, 52.9% (9/17). Of the active disease group at baseline, 50% (6/12) remained stable post-switch. There was a trend between baseline clinical status and biosimilar persistence (P = .06). Continuation of the biosimilar within the controlled group was 64.8% (79/122), compared with the partially controlled group at 35.3% (6/17) and the active disease group at 66.7% (8/11). Those who discontinued the biosimilar post-switch were due to worsening disease (45.8%), new adverse effects (17%), insurance changes (11.9%), and other reasons (25.5%). Other reasons included device difficulties, patient preference, and initiation of a different biologic. Routine Assessment of Patient Index Data 3 results were available for 104 patients (68.4%). There was no statistically significant change in RAPID3 scores from baseline to follow-up (mean change +0.59, P = .10; signed rank P = .18). When stratified by baseline disease-control group, RAPID3 change did not differ significantly across groups (ANOVA P = .3905; Kruskal-Wallis P = .6051), and no pairwise comparisons were significant. The median OOP copay for reference adalimumab was $5.00 (IQR, $0.00, $5.00). The median copay for the post-switch biosimilar was $0.00 (IQR, $0.00, $2.00). The median post-switch cost change was $0. However, the mean cost decrease post-switch was reported as a difference of $22.60. This high variability is driven by outliers rather than a consistent cost reduction across the cohort (Table 3). Table 3.Reference Product Adalimumab and Biosimilar Copay Analysis.VariableNMedian [IQR]Mean ± SDReference adalimumab Copay885.00 [0.00, 5.00]24.2 ± 188.4Biosimilar copay900.00 [0.00, 2.00]14.5 ± 98.3Cost change (Biosimilar – reference)790.00 [−5.00, 0.00]−22.6 ± 199.4Values are presented as median [IQR] and mean ± SD. Cost change was calculated as biosimilar copay minus reference adalimumab copay; negative values indicate lower copay after switching. Reference Product Adalimumab and Biosimilar Copay Analysis. Values are presented as median [IQR] and mean ± SD. Cost change was calculated as biosimilar copay minus reference adalimumab copay; negative values indicate lower copay after switching. Discussion In this retrospective cohort of patients undergoing nonmedical, insurance-mandated switches from reference adalimumab to adalimumab biosimilars, most patients remained clinically stable following a switch. However, the findings were not uniform across baseline disease states. Among patients controlled at baseline, nearly one-third worsened by follow-up, whereas improvement was observed primarily among patients who were partially controlled or had active disease at baseline. Since the partially controlled and active disease subgroups were small (n = 17 and n = 12), and because baseline disease-state categories impose ceiling and floor effects, these subgroup findings should be interpreted as exploratory rather than as definitive evidence that switching changes disease activity. Notably, the existing literature works, including systematic reviews of randomized switching trials, have consistently demonstrated comparable efficacy between adalimumab biosimilars and the reference product with no significant improvement attributable to the switch itself.8-10 However, pharmacists and other clinicians may still be apprehensive about switching when the indication is an insurance requirement. Our study adds to the literature in providing reassurance about the safety of switching for this indication. Biosimilars are proposed to be more cost-effective for both the payer and the patient. 2 However, it remains debated whether OOP costs have decreased for patients when switched to biosimilars. A cohort study of seven biologics found that biosimilar claims were more likely to have nonzero OOP costs than reference biologics (adjusted odds ratio, 1.13), though when costs were nonzero, biosimilar OOP costs were 8% lower on average. 11 A propensity-matched study of patients switching from reference adalimumab to adalimumab-atto similarly found only a modest mean monthly OOP decrease of $51 in switchers versus $11 in nonswitchers (P < .01). 9 These findings suggest that while biosimilar competition may reduce overall drug spending, patient-level OOP savings remain variable and likely depend on insurance plan design, copay assistance programs, and rebate structures. 12 Pharmacists and pharmacy teams should be aware that some patients switched to biosimilars may encounter higher OOP costs, and additional counseling, copay assistance enrollment, or manufacturer discount program coordination may be necessary to mitigate unexpected financial burden and support medication adherence. In our study, the median change in cost post-switch identified minimal copay decreases from no change up to a decrease of $2.00. While the mean favors the biosimilar for a cost reduction of $22.60, this was driven by a small number of outliers rather than a consistent reduction across patients, and the median cost change of $0 more accurately reflects the typical patient’s experience. This is reflected in the large standard deviation of the mean ± SD = −22.6 ± 199.4. In addition, copay data were only available for patients who used our institutional specialty pharmacy, and the analysis reflected costs after copay assistance had already been applied, which may mask the full financial impact of the switch. Further research is needed to clarify whether biosimilar switching consistently reduces patient-level costs. A strength of this study included patients serving as their own control. This allowed us to eliminate individual characteristics as potential confounders. This study also reflected a real-world clinic, where pharmacists were able to follow-up with patients and manage disease flares or therapy changes if needed. While disease assessment was not performed during these encounters, pharmacists were able to triage flares or worsening disease to providers, assist with biosimilar changes, or complete therapy changes through their collaborative practice agreement. Several limitations are important to note when interpreting subgroup changes in disease activity. First, there was no nonswitched comparison group, so temporal trends cannot be accounted for. Second, the partially controlled and active disease subgroups were small (n = 17 and n = 12, respectively), limiting precision and generalizability. The improvements observed in the partially controlled and active disease subgroups in this study likely reflect natural disease fluctuation, regression to the mean, or concurrent treatment adjustments rather than a therapeutic benefit of the biosimilar. Third, provider-assessed disease activity was categorized ordinally as controlled, partially controlled, or active disease, creating ceiling and floor effects: patients controlled at baseline could remain stable or worsen but could not improve, while patients with active disease could remain active or improve but could not worsen further on this scale. Since patients at either end of this scale could only move in one direction, these subgroups are susceptible to regression to the mean, where patients at the extremes will tend to shift toward the center on repeat assessment regardless of whether any intervention was made. In addition, clinical trials of reference adalimumab typically evaluate a single disease state and efficacy outcomes were based on the American College of Rheumatology (ACR) response criteria and the Disease Activity Score 28 (DAS28) as primary efficacy endpoints. Provider-assessed disease activity was chosen as the primary outcome in our study because it drives real-world treatment decisions; however, it is subjective, and future studies should incorporate validated disease scoring methods such as DAS28, ASDAS, or RAPID3. In our study, RAPID3 data were incomplete and not available for all follow-up encounters, limiting interpretation of patient-reported disease activity. In addition, RAPID3 has been validated for rheumatoid arthritis. However, its validity in psoriatic arthritis and ankylosing spondylitis has been explored but is less well established. Since this study included patients across numerous rheumatoid diagnoses, the reliability of RAPID3 outcomes may vary across the cohort. There are other limitations to note. As this was a retrospective chart review, the primary outcome was dependent on the accuracy of documentation provided in the electronic health record. The lack of diversity of the population also limits the generalizability of these findings. In addition, our study did not perform a product-level analysis to determine whether outcomes differed by specific biosimilar, as the sample size would have resulted in underpowered subgroups; however, real-world evidence suggests that product-level differences may exist and warrant investigation in larger cohorts. 10 Clinical trials of reference adalimumab also discuss the immunogenicity of adalimumab, resulting in decreased efficacy over time. This was not measured in this study, as immunogenicity testing is not routine for our patients. Notably, systematic reviews of biosimilar switching have found no significant differences in antidrug antibody rates between patients who switched from reference adalimumab to biosimilars and those who continued the reference product, suggesting that switching itself does not appear to increase immunogenicity risk.2,8,9 Conclusion Nonmedical, insurance-mandated switching from reference adalimumab to biosimilar therapy did not appear to meaningfully impact disease control for most patients. In addition, median out-of-pocket costs did not change after switching. These findings should reassure pharmacists when helping patients with insurance-mandated adalimumab biosimilar switches. Further research is warranted to evaluate the potential disease state changes and cost savings associated with nonmedical insurance-mandated switches from reference adalimumab to biosimilars. Supplemental Material sj-docx-1-pmt-10.1177_87551225261479593 – Supplemental material for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population Supplemental material, sj-docx-1-pmt-10.1177_87551225261479593 for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population by Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G. Kennedy and Julie MacDougall in Journal of Pharmacy Technology sj-png-1-pmt-10.1177_87551225261479593 – Supplemental material for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population Supplemental material, sj-png-1-pmt-10.1177_87551225261479593 for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population by Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G. Kennedy and Julie MacDougall in Journal of Pharmacy Technology Footnotes Authors’ Note: Prior Poster: Presented at Vizient Mid-Year Residency Presentation in Las Vegas, NV, 2025. ORCID iDs: Krista Dessureault https://orcid.org/0009-0000-0830-8278 Amanda G. Kennedy https://orcid.org/0000-0002-7540-4961 Julie MacDougall https://orcid.org/0000-0002-4087-2853 Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Supplemental Material: Supplemental material for this article is available online. References Associated Data Supplementary Materials sj-docx-1-pmt-10.1177_87551225261479593 – Supplemental material for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population Supplemental material, sj-docx-1-pmt-10.1177_87551225261479593 for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population by Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G. Kennedy and Julie MacDougall in Journal of Pharmacy Technology sj-png-1-pmt-10.1177_87551225261479593 – Supplemental material for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population Supplemental material, sj-png-1-pmt-10.1177_87551225261479593 for Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population by Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G. Kennedy and Julie MacDougall in Journal of Pharmacy Technology